You just read:

Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache

News provided by

Eli Lilly & Company

Nov 14, 2018, 06:45 ET